BACKGROUND: The aim of this study was to evaluate the incidence of malignancy in small testicular masses (STMs) treated with testis-sparing surgery (TSS) with intraoperative frozen section analysis and to assess the safety of this surgical procedure.
PATIENTS AND METHODS: From January 2009 to January 2013, 15 consecutive patients underwent TSS for STMs in a third-referral academic institution. Every patient was preoperatively evaluated with clinical examination and scrotal ultrasonography (US) performed by the same radiologist. Tumor markers were assessed in all cases. All the procedures were performed through inguinal access; the small mass was identified by straight palpation of the testis or with intraoperative ultrasonography (IUS). Frozen-section examination (FSE) was performed in all patients in association with multiple biopsies of the surrounding tissue. Follow-up was carried out in all patients with an ultrasonographic exploration at 6 and 12 months.
RESULTS: Preoperative tumor markers were normal in all patients. The mean operative time was 90 ± 31 minutes. The warm ischemia time was 18 ± 3 minutes. The mean size on US was 9.5 ± 4.4 mm. FSE results were confirmed by the final pathologic analysis in 14 patients. At final pathologic analysis, 6 patients (40%) were found not to have tumors, another 7 patients (46.7%) had benign neoplasms, and malignant tumor was found in only 2 patients (13.3%). There was no disease recurrence after a mean follow-up of 19.2 ± 11.5 months.
CONCLUSION: Our experience shows that TSS performed for STMs may represent a safe procedure with optimal results in terms of functional and oncologic end points.
Written by:
Gentile G, Brunocilla E, Franceschelli A, Schiavina R, Pultrone C, Borghesi M, Romagnoli D, Cevenini M, Dababneh H, Corcioni B, Gaudiano C, Gacci M, Golfieri R, Martorana G, Colombo F. Are you the author?
Department of Urology, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.
Reference: Clin Genitourin Cancer. 2013 Jun 10. pii: S1558-7673(13)00129-8.
doi: 10.1016/j.clgc.2013.04.033
PubMed Abstract
PMID: 23764019
UroToday.com Testicular Cancer Section
